Search company, investor...
Search

Predict your next investment

Cipla company logo
Corporation
HEALTHCARE | Pharmaceuticals / Drugs
cipla.com

See what CB Insights has to offer

Investments

7

Partners & Customers

10

About Cipla

Cipla (BSE: 500087) (NSE: CIPLA) is a multinational pharmaceutical and biotechnology company. Cipla primarily develops medicines to treat cardiovascular disease, arthritis, diabetes, weight control, and depression, as well as other medical conditions.

Cipla Headquarters Location

Cipla House, Peninsula Business Park Ganpatrao Kadam Marg, Lower Parel

Mumbai, 400 013,

India

+91 22 23082891

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cipla

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Cipla in 1 Expert Collection, including Diabetes.

D

Diabetes

1,750 items

Cipla Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cipla Rank

Latest Cipla News

Another Cipla site lands a Form 483 over cleaning issues and QC controls

Oct 1, 2022

Tyler Patchen News Reporter A Cipla drug manufacturing site in India has once again landed in the crosshairs of FDA inspectors. The facility in question is Cipla’s drug manufacturing facility in the village of Verna, in the state of Goa in India’s southwest. In a sign that foreign inspections might ramp up again, the FDA’s visit from Aug. 16 to Aug. 22 uncovered six observations. The 11-page report noted that environmental monitoring at the site did not properly ensure that microbial contaminants were not making any impact in the aseptic filling areas. It also found that procedures meant to stop microbial contamination were not adequately conducted in aseptic areas of the facility. Keep reading Endpoints with a free subscription Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Amber Tong Senior Editor Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers  can visit their reader profile  to add Endpoints Weekly. New to Endpoints? Sign up here . Reading about John Carroll’s pick of biotech’s most promising startups has become a treasured tradition. If you ever get curious about previous classes of the Endpoints 11, you can find all of them (plus a number of our other regular specials) here . Keep reading Endpoints with a free subscription Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Kyle LaHucik Associate Editor FDA’s outside advisors voted in favor of Ferring Pharmaceuticals’ RBX2660, an experimental poop-based drug implant that the company says would be the first microbiota-based live biotherapeutic to receive an FDA green light. That was a point repeatedly discussed during the Vaccines and Related Biological Products Advisory Committee, or VRBPAC, meeting Thursday when evaluating Ferring’s fecal microbiota transplant, or FMT, for reducing the recurrence of Clostridioides difficile infection in adults who have received antibiotics. Multiple members brought up the need for a regulated product amid a landscape of unregulated FMTs already happening in clinical care. Keep reading Endpoints with a free subscription Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Beth Snyder Bulik Senior Editor At Klick Health’s first Ideas Exchange conference with biotech and pharma industry insiders since before the pandemic began, it was no surprise many conversations included Covid topics. Yet while vaccines and treatments were discussed, so too were the effects on drug development, federal responses, health inequities — and what to do now and next. George Yancopoulos, chief scientist and cofounder of Regeneron, opened the conference responding to a question from Acorda CEO Ron Cohen about the spotlight on the industry during Covid and some of the “flak” biopharma has taken in the past. Read More Nicole DeFeudis Editor Weeks after announcing the spinoff of generics arm Sandoz, Vas Narasimhan paints a picture of the new, slimmer Novartis — with a “US-first mindset,” he said at an investor event on Thursday. The CEO unveiled ambitious plans to become a top-five player in the US by 2027 at Novartis’ “Meet the Management” event in Basel, Switzerland, which means ramping up clinical trials in the states and “building capability and talent, among other things.” The company’s also shooting for a top-three ranking in China. Keep reading Endpoints with a free subscription Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Beth Snyder Bulik Senior Editor If pharma advertising had a fantasy football league, Pfizer would be crushing the competition. A dive into the National Football League’s TV commercial buys across early season games by iSpot shows a hefty lead with its Covid-19 Comirnaty vaccine ads. More than 175 million impressions with $9.5 million in media spending put Pfizer in the top spot with a 65% share of voice across NFL pharma spending, according to the real-time TV ad tracker. In a distant second place is Bristol Myers Squibb’s Opdivo with 44 million impressions, $5.2 million in spending and a 16% share, followed by BMS’ Zeposia with 31 million impressions, $3.3 million in media buys and an 11% share. Keep reading Endpoints with a free subscription Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free. SIGN UP LOG IN

Cipla Investments

7 Investments

Cipla has made 7 investments. Their latest investment was in GoApptiv as part of their Corporate Minority - II on June 6, 2022.

CBI Logo

Cipla Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/27/2022

Corporate Minority - II

GoApptiv

$3.3M

No

1

6/18/2022

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

3/31/2021

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

6/10/2020

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

2/18/2019

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/27/2022

6/18/2022

3/31/2021

6/10/2020

2/18/2019

Round

Corporate Minority - II

Corporate Minority

Corporate Minority

Corporate Minority

Corporate Minority

Company

GoApptiv

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$3.3M

$99M

$99M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

10

Cipla Acquisitions

12 Acquisitions

Cipla acquired 12 companies. Their latest acquisition was Wanbury - CPink, CDense, Productiv, Folinine on February 10, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

2/10/2020

$99M

Acquired Unit

1

12/9/2019

Other

$99M

Acquired

3

7/12/2018

$99M

Acquired

4

4/1/2017

Subscribe to see more

$99M

Subscribe to see more

10

9/4/2015

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/10/2020

12/9/2019

7/12/2018

4/1/2017

9/4/2015

Investment Stage

Other

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

Note

Acquired Unit

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

1

3

4

10

10

Cipla Partners & Customers

10 Partners and customers

Cipla has 10 strategic partners and customers. Cipla recently partnered with Merck & Co. on December 12, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

12/28/2021

Licensee

United States

1

8/25/2021

Partner

India

Cipla, Kemwell Biopharma form JV for developing, manufacturing biosimilars

Guided by our purpose of ` Caring for life ' our partnership with Kemwell will help serve unmet needs of patients across the globe , '' said Umang Vohra , managing director and global chief executive officer of Cipla Ltd .

5

8/25/2021

Partner

India

Cipla and Kemwell Biopharma announce execution of a joint venture agreement for developing, manufacturing and commercialising biosimilars Cipla And Kemwell Biopharma Announce Execution Of A Joint Venture Agreement For Developing, Manufacturing And Commercialising Biosimilars.

Mumbai , India , August 25 , 2021 : Cipla Limited , a leading global pharmaceutical company and Kemwell , a leading biopharmaceutical Contract Development and Manufacturing Organisation , announced execution of a joint venture agreement to develop , manufacture and commercialise biosimilars for global markets .

1

6/29/2021

Partner

India

Subscribe to see more

Subscribe to see more

10

5/21/2021

Partner

India

Subscribe to see more

Subscribe to see more

10

Date

12/28/2021

8/25/2021

8/25/2021

6/29/2021

5/21/2021

Type

Licensee

Partner

Partner

Partner

Partner

Business Partner

Country

United States

India

India

India

India

News Snippet

Cipla, Kemwell Biopharma form JV for developing, manufacturing biosimilars

Guided by our purpose of ` Caring for life ' our partnership with Kemwell will help serve unmet needs of patients across the globe , '' said Umang Vohra , managing director and global chief executive officer of Cipla Ltd .

Cipla and Kemwell Biopharma announce execution of a joint venture agreement for developing, manufacturing and commercialising biosimilars Cipla And Kemwell Biopharma Announce Execution Of A Joint Venture Agreement For Developing, Manufacturing And Commercialising Biosimilars.

Mumbai , India , August 25 , 2021 : Cipla Limited , a leading global pharmaceutical company and Kemwell , a leading biopharmaceutical Contract Development and Manufacturing Organisation , announced execution of a joint venture agreement to develop , manufacture and commercialise biosimilars for global markets .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

5

1

10

10

Cipla Team

5 Team Members

Cipla has 5 team members, including , .

Name

Work History

Title

Status

Raj Tanwar

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Raj Tanwar

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

You May Also Like

R
Ranbaxy

Ranbaxy is a pharmaceutical distributor.

Aurobindo Pharma Logo
Aurobindo Pharma

Aurobindo Pharma (NSE: AUROPHARMA) manufactures pharmaceutical products, which include anti-retroviral medicines, antibiotics, gastroenterological medicines, anti-diabetics medicines, anti-allergic medicines, etc. Apart from Pharmaceutical businesses, it also caters to drug formulation. The company was founded in 1986 and is based in Telangana, India.

Sun Pharma Logo
Sun Pharma

Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in US, India and several other markets across the world.

Lupin Logo
Lupin

Lupin (NSE: LUPIN) is a transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs.

Dr. Reddy's Laboratories Logo
Dr. Reddy's Laboratories

Dr. Reddy's Laboratories (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) is an integrated pharmaceuticals company. Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, and differentiated formulations. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy's Laboratories was founded in 1984 and is based in Hyderabad, India.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.